XN000022-1995-07-26 — Page 28

16

Since the standard scale has not taken into account past inflation, a review of existing fines under the Housing Ordinance is necessary. We have completed the review. We now propose to increase the fines under five sections, namely, 26(1), 27, 28(1), 28(2) and 29, to the appropriate levels on the standard scale as indicated. Two other sections, namely, 26(2) and 27A, fall outside the standard scale. They deal with the more serious offences of giving false information in the purchase of subsidised home ownership flats and their unlawful alienation. We propose to increase the fines absolutely from $200,000 to $500,000, also to reflect the effect of inflation up to 1994.

Mr President, I beg to move.

End/Wednesday, July 26, 1995

Pharmacy and Poisons (Amendment) (No.2) Regulation 1995

Following is the speech by the acting Secretary for Health and Welfare, Mrs Shelley Lau, in moving the Pharmacy and Poisons (Amendment)(No.2) Regulation 1995 in the Legislative Council today (Wednesday):

Mr President,

I move the motion standing in my name in the Order Paper that the Pharmacy and Poisons (Amendment) (No.2) Regulation 1995 be approved.

The Pharmacy and Poisons Ordinance and its subsidiary legislation regulate, inter alia, the registration of pharmaceutical products.

The Amendment Regulation which was made by the Pharmacy and Poisons Board on 26 June 1995 seeks to clarify the procedures and requirements involved in changing the particulars of registered pharmaceutical products.

Currently, details such as the names and composition of pharmaceutical products are particulars which are required to be registered before these products are permitted to be sold or distributed.

If approved, the Amendment Regulation will make it clear that the change of particulars of registered pharmaceutical products will be permitted only if the change does not affect the safety, efficacy and quality and does not involve those particulars which affect the identity of the products. The change, therefore, needs to be approved before it can be effected and before the product with changed particulars can be sold or distributed.